HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donadio, J. V Search for Related Content PubMed PubMed Citation Articles by Donadio, J. V, Jr Agricola Articles by Donadio, J. V

Use of fish oil to treat patients with immunoglobulin A nephropathy^1,2,3

¹ From the Mayo Clinic and Mayo Foundation, Rochester, MN.

This review describes the use of fish oil in the treatment of patients with immunoglobulin (Ig) A nephropathy. IgA nephropathy is the most common glomerular disease worldwide. It has a variable course and leads to end-stage renal disease in a substantial number of cases. Among the 4 published randomized clinical trials that tested the efficacy of fish-oil treatment of IgA nephropathy, 2 reported beneficial effects on renal function and 2 showed negative results. In the largest trial conducted by my collaborative study group, convincing evidence was provided for protection against progressive renal disease after daily treatment for 2 y with fish oil providing 1.8 g eicosapentaenoic acid and 1.2 g docosahexaenoic acid—the 2 major n-3 polyunsaturated fatty acids in fish oil. Oral prednisone has also been advocated, especially in the treatment of children with IgA nephropathy. Two randomized trials are currently underway in the United States to resolve the discrepancy of results in previous fish-oil trials and to determine whether corticosteroids or fish oil is the better treatment of patients at risk for developing progressive disease; results of these studies are not yet available.

Key Words: Immunoglobulin A nephropathy • treatment • fish oil • renal disease

This article has been cited by other articles:

				R. A. Siddiqui, K. A. Harvey, G. P. Zaloga, and W. Stillwell Modulation of Lipid Rafts by {Omega}-3 Fatty Acids in Inflammation and Cancer: Implications for Use of Lipids During Nutrition Support Nutr Clin Pract, February 1, 2007; 22(1): 74 - 88. [Abstract] [Full Text] [PDF]

				M. Zeyda, M. D. Saemann, K. M. Stuhlmeier, D. G. Mascher, P. N. Nowotny, G. J. Zlabinger, W. Waldhausl, and T. M. Stulnig Polyunsaturated Fatty Acids Block Dendritic Cell Activation and Function Independently of NF-{kappa}B Activation J. Biol. Chem., April 8, 2005; 280(14): 14293 - 14301. [Abstract] [Full Text] [PDF]

				Q. Jia, H.-R. Zhou, M. Bennink, and J. J. Pestka Docosahexaenoic Acid Attenuates Mycotoxin-Induced Immunoglobulin A Nephropathy, Interleukin-6 Transcription, and Mitogen-Activated Protein Kinase Phosphorylation in Mice J. Nutr., December 1, 2004; 134(12): 3343 - 3349. [Abstract] [Full Text] [PDF]

				M. L. Kielar, D. R. Jeyarajah, X. J. Zhou, and C. Y. Lu Docosahexaenoic Acid Ameliorates Murine Ischemic Acute Renal Failure and Prevents Increases in mRNA Abundance for both TNF-{alpha} and Inducible Nitric Oxide Synthase J. Am. Soc. Nephrol., February 1, 2003; 14(2): 389 - 396. [Abstract] [Full Text] [PDF]